LYELbenzinga

Lyell To Present Initial Clinical Data From Phase 1-2 Trial Of IMPT-314 CAR T-Cell Therapy For B-Cell Lymphoma At ASH 2024, Highlighting Fast Track Designation And Dual-Targeting CD19/CD20 Approach

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 5, 2024 by benzinga